Orbit (Amsterdam, Netherlands) · 2026
Lacrimal sac squamous cell carcinoma: diagnostic challenges, surgical management and clinical outcomes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Niinimäki Paula, Haglund Caj, Jaana Hagström, Vuola Jyrki, Tynninen Olli, Haapaniemi Aaro, Mäkitie Antti, Kivelä Tero T, Uusitalo Marita
Аннотация
PURPOSE: To evaluate the incidence, clinical features, diagnostic challenges, patient and healthcare-related delays, management, and outcomes of lacrimal sac squamous cell carcinoma (lsSCC) at a tertiary care centre.
METHODS: We identified patients from the Finnish Cancer Registry and the Helsinki University Hospital (HUS, Helsinki, Finland) databases over a 16-year period 2007-2022 and analysed clinical features, histopathology, human papillomavirus (HPV) positivity by immunohistochemical staining for p16INK4A (p16) and mRNA detection by in situ hybridization for high-risk HPV (HR-HPV), and treatment.
RESULTS: The median age at diagnosis for the 13 patients was 67 years (range, 40-97). Median time to histopathologic diagnosis of lsSCC was 6 months (range, 0-36). The most common reason for delay was treatment based on an incorrect diagnosis of dacryocystitis. Eye-sparing surgery was performed in eight (62%) and exenteration in five (38%) patients. Differentiation was classified as grade 2 in 38% and grade 3 in 62% of tumours. Eight of 12 analysed tumours (67%) were HPV positive. The reconstruction method involved a microvascular flap in 54% and a local pedicular skin or fascia flap in 46% of patients. Ten patients received postoperative external beam radiotherapy, and one patient received chemotherapy. The median follow-up time was 5 years (range, 0-17). The patient with regional micrometastasis developed systemic metastatic disease at 11 months and died of metastatic lsSCC 22 months after surgery.
CONCLUSION: Two-thirds of the patients had an HR-HPV-positive tumour. Diagnosis of lsSCC is often delayed. Despite high tumour grade, recurrences and metastasis of lsSCC were rare in this cohort.
METHODS: We identified patients from the Finnish Cancer Registry and the Helsinki University Hospital (HUS, Helsinki, Finland) databases over a 16-year period 2007-2022 and analysed clinical features, histopathology, human papillomavirus (HPV) positivity by immunohistochemical staining for p16INK4A (p16) and mRNA detection by in situ hybridization for high-risk HPV (HR-HPV), and treatment.
RESULTS: The median age at diagnosis for the 13 patients was 67 years (range, 40-97). Median time to histopathologic diagnosis of lsSCC was 6 months (range, 0-36). The most common reason for delay was treatment based on an incorrect diagnosis of dacryocystitis. Eye-sparing surgery was performed in eight (62%) and exenteration in five (38%) patients. Differentiation was classified as grade 2 in 38% and grade 3 in 62% of tumours. Eight of 12 analysed tumours (67%) were HPV positive. The reconstruction method involved a microvascular flap in 54% and a local pedicular skin or fascia flap in 46% of patients. Ten patients received postoperative external beam radiotherapy, and one patient received chemotherapy. The median follow-up time was 5 years (range, 0-17). The patient with regional micrometastasis developed systemic metastatic disease at 11 months and died of metastatic lsSCC 22 months after surgery.
CONCLUSION: Two-thirds of the patients had an HR-HPV-positive tumour. Diagnosis of lsSCC is often delayed. Despite high tumour grade, recurrences and metastasis of lsSCC were rare in this cohort.
Предметные рубрики MeSH
HumansFemaleCarcinoma, Squamous CellAgedMaleEye NeoplasmsLacrimal Apparatus DiseasesMiddle AgedAdultAged, 80 and overFinlandImmunohistochemistryHuman Papillomavirus VirusesIn Situ HybridizationPapillomavirus InfectionsIncidenceTreatment OutcomeOphthalmologic Surgical ProceduresCyclin-Dependent Kinase Inhibitor p16